What Are the Clinical Implications of MUSTT?

  • S. L. Higgins
Conference paper


The Multicenter Unsustained Tachycardia Trial (MUSTT) findings have yet to be published. However, as a result of presentation of the preliminary results at two major cardiology meetings, the publication is much anticipated. Since it is unpublished, its true clinical impact has yet to be determined. However, based on the response to similar important trials in arrhythmia management, we can make reasonable projections of the potential clinical relevance of this trial.


Arrhythmic Death Ventricular Tachy Multicenter Automatic Defibrillator Implantation Trial Arrhythmia Management European Myocardial Infarct Amiodarone Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Buxton AE, Fisher JD, Josephson ME, Lee KL, Pryor DB, Prystowsky EN, Simson MB, DiCarlo L, Echt DS, Packer D, Greer GS, Talajic M, the MUSTT Investigators (1993) Prevention of sudden death in patients with coronary artery disease: the multicenter unsustained tachycardia trial (MUSTT). Prog Cardiovasc Dis 6:215–226CrossRefGoogle Scholar
  2. 2.
    MADIT Executive Committee (1991) Multicenter automatic defibrillator implantation trial (MADIT): design and clinical protocol. PACE 14(II):920–927CrossRefGoogle Scholar
  3. 3.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defìbriïlator Implantation Trial (MADIT) Investigators (1996) Improved survival with an implanted derìbrülator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933–1940PubMedCrossRefGoogle Scholar
  4. 4.
    Higgins SL (1999) Impact of the Multicenter Automatic Defibrillator Implantation Trial (MADIT) on ICD indication trends: a two-year perspective. Am J Cardiol 83:79D–82DPubMedCrossRefGoogle Scholar
  5. 5.
    Higgins SL, Klein H, Nisam S (1997) Which device should “MADIT protocol” patients receive? Am J Cardiol 79:31–35PubMedCrossRefGoogle Scholar
  6. 6.
    Higgins SL, Daubert JL, Akhtar M (1997) Who are the MADIT patients? Am J Cardiol 79(5B):42–46FCrossRefGoogle Scholar
  7. 7.
    Higgins SL, Voshage-Stahl L (1997) What have we learned from the US experience on the prophylactic use of ICDs following MADIT? In: Raviele A (ed) Cardiac Arrhythmias. Springer-Verlag, Milan, pp 270–275Google Scholar
  8. 8.
    Higgins S (1997) Will management of atrial arrhythmias be important in MADIT patients? In: Capucci A (ed) Atrial fibrillation, evolving concepts and new therapeutic strategies. BolognaGoogle Scholar
  9. 9.
    Nisam S (1997) Do MADIT results apply only to “MADIT Patients”? Am J Cardiol 79(6A):27–30PubMedCrossRefGoogle Scholar
  10. 10.
    National Heart, Lung and Blood Institutes Communications (1997) NHLBI stops arrhythmia study-implantable cardiac defibrillators reduce deaths. NIH press release, April 14Google Scholar
  11. 11.
    Bocker D, Block M, Borggrefe M, Breithardt M (1997) Evidence-based cardiology: defibrillators are superior to anti-arrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J 18:26–30PubMedCrossRefGoogle Scholar
  12. 12.
    Cannom DS (1998) A review of the implantable cardioverter defibrillator trials. Curr Opin Cardiol 13:3–8PubMedCrossRefGoogle Scholar
  13. 13.
    Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ (1988) The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT: Multicenter Automatic Defibrillator Implantation Trial. Circulation 97:2129–2135CrossRefGoogle Scholar
  14. 14.
    Viskins S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, Zajanas A, Laniado S, Beihassen B (1995) Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 25:1327–1332CrossRefGoogle Scholar
  15. 15.
    Garg R, Yusuf S, Collaborative Group on ACE Inhibitor Trials (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 18:1450–1456CrossRefGoogle Scholar
  16. 16.
    The AVID investigators (1997) A comparison of anti-arrhythmic drug therapy with implantable defìbrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 337:1576–1583CrossRefGoogle Scholar
  17. 17.
    Cairns JA, Connolly SJ, Roberts R, Gent M (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 49:675–682Google Scholar
  18. 18.
    Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 49:667–674Google Scholar
  19. 19.
    Maloney JD (1989) Consequences of the Cardiac Arrhythmia Suppression Trial: calamity or clarity? Clev Clin J Med 56:649–653Google Scholar
  20. 20.
    Friedman P, Stevenson W (1996) Unsustained ventricular tachycardia-to treat or not to treat. N Engl J Med 335:1984–1985 (editorial)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • S. L. Higgins
    • 1
  1. 1.Regional Cardiac Arrhythmia CenterScripps Memorial HospitalLa JollaUSA

Personalised recommendations